METOPROLOL TARTRATE

Post-LOE

metoprolol tartrate

Molecular Devices

ANDAORALTABLET

Approved

Mar 1994

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

METOPROLOL TARTRATE (metoprolol tartrate) by Molecular Devices is 12. Approved for hypertension in adult patients, to lower blood pressure, the long-term treatment of angina pectoris in adult patients and 7 more indications. First approved in 1994.

Drug data last refreshed 1w ago

Mechanism of Action

12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…

Worked on METOPROLOL TARTRATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

METOPROLOL TARTRATE

Mechanism of Action

Indications (9)

Clinical Trials (1)